StockWatch
·

Concord Control Systems Ltd Q2 FY27 Results

CNCRDQ2 FY27 Results
Filing
MetricValue (₹ Cr)Q2 FY26
Revenue159.1195.1%
Total Income161.1794.2%
Expenditure117.7991.7%
PBT42.2695.9%
Net Profit31.1180.2%
OPM—
NPM19.30%1.50pp
EPS30.0818.4%
View full financials
CONCORD CONTROL SYSTEMS · Q2 FY-2027 · THE VERDICT

₹159 Crore Surge, But Platforms Still in Beta

Concord delivered strong revenue growth (+95% YoY) and upgraded order book to ₹846 Cr, but management overstated profit growth (claimed 95%, actual 80.2%) and kept guidance flat. The quarter is operationally solid, but the 40–50% CAGR story depends on executing Kavach approval, Fusion ramp, and hydrogen platforms that remain early-stage.

11 Nov 2026 · 6 min read
Revenue

₹159 Cr

+95.1% YoY

Management claimed PAT growth

~95%

on the call

Actual PAT growth

80.2%

₹31.1 Cr vs ~₹17.3 Cr PY

EBITDA margin

29.3%

beat 20–25% prior guidance

On the earnings call, management highlighted profit growth at approximately 95%, aligning with revenue expansion. The delivered number tells a different story: PAT grew 80.2% YoY to ₹31.1 Cr, lagging the revenue surge by 15 percentage points. It's not a crater, but it is selective framing — the company nailing revenue and margin, but softening the profit narrative. Revenue and EBITDA, by contrast, are clean: ₹159 Cr (+95% organic), EBITDA margin at 29.3% beats prior guidance of 20–25%. Order book upgraded mid-year to ₹846 Cr, providing 4× annual revenue in backlog.

What the quarter actually was

Concord ran a textbook execution quarter: revenue delivery, margin expansion, working capital discipline, and a record order book. The company is on track for its stated 40–50% CAGR over the next 3–5 years, anchored by ₹846 Cr in orders spanning locomotives, Kavach safety systems, hydrogen propulsion, and Fusion PCB. Advanced Rail (locomotives + safety) now represents >80% of revenue; legacy Fusion (acquired earlier) is in production-ready state, targeting ₹400 Cr revenue at full scale. Debtor days improved to 178 from 210; inventory tightened from 313 to 259 days — railway projects are inherently long-cycle, so this is sound working capital management.

Management's key claims vs. what holds up

Revenue grown ~95% YoY to ~₹159 Cr

₹159.1 Cr, +95.1% YoY from ~₹81.6 Cr PY

Supported

Profits up ~95% to ₹31.2 Cr

₹31.1 Cr, +80.2% YoY, not 95%

Overstated by ~15pp

EBITDA margin 29.30%, up ~110% YoY

Margin 29.34%; prior EBITDA ~₹21 Cr, current ₹46.7 Cr

Supported

Order book ₹846 Cr as of 30-Sep-2026

Opening ₹697 Cr + received ₹308 Cr − executed ₹159 Cr = ₹846 Cr

Supported; mathematically verified

40–50% CAGR target over 3–5 years

H1 FY27 at 95% growth; ₹846 Cr backlog provides multi-year visibility

Supported by execution

Margins sustainable at 29–30% (vs prior 20–25% guidance)

Delivered 29.3%; no upside above 30% flagged by management

Floor solid; ceiling appears soft

What changed on this call

Order book upgraded. Mid-year jump from ₹697 Cr (FY-2026 guidance) to ₹846 Cr (+₹149 Cr, +21%) driven by new Kavach, hydrogen propulsion, and green-mobility orders. Margin beat. Delivered 29.3% vs prior guidance of 20–25%; economies of scale from order execution flowing through faster than expected. Fusion PCB production live. Backward integration complete for cost reduction; 30–40% of PCBA capacity initially utilized; target ₹400 Cr revenue at full scale by FY27–28. Hydrogen propulsion order in hand. ₹3,100 HP (horsepower) single order received; execution by next year, first deployment after battery locomotive success (running 12+ months).

The bull-bear ledger
  • Record order book (₹846 Cr) covers 3–4 years at current execution rate

  • EBITDA margin beat (29% vs 20–25% prior guidance); economies of scale showing

  • Railway electrification & green mobility are govt priorities (10+ year tailwind)

  • Fusion PCB backward integration de-risks cost and supply chain

  • PAT growth overstated (claimed 95%, actual 80.2%) — signals selective reporting

  • Kavach approval timeline vague; ISA cycle could slip 12–24 months

  • Hydrogen & battery propulsion platforms early-stage; execution risk high

  • 80% of order book from Indian Railways; limited diversification

  • International expansion (FY30 target: 1/4–1/2 revenue) timeline uncertain

Risks, ranked by how much they should concern a holder

Kavach ISA approval slip

High

₹100–120 Cr order book hinges on certification. Delay pushes revenue to FY28+, materially impacting CAGR trajectory.

Hydrogen propulsion execution risk

High

₹3,100 HP order new; technology unproven at scale. Supply chain (fuel cell, tank) and integration risk could cause delays or cost overruns.

Customer concentration (80% Indian Railways)

High

Revenue dependent on govt buyer. Policy shift (e.g., electrification slowdown) or capex cuts would crater order flow.

Fusion PCB ramp-up slower than expected

Medium

Initially 30–40% PCBA capacity; flex/rigid PCB market competitive. Underutilization or margin erosion could offset ₹400 Cr target.

EBITDA margin plateau at 29–30%

Medium

No upside flagged above 30%; economies of scale may offset inflation, but no expansion narrative beyond current level.

International partnerships take longer than FY30 target

Medium

1/4–1/2 revenue from global by FY30 is aspirational; conversion from InnoTrans partnerships multi-year and unpriced.

How the street is positioned

The stock sits at ₹2,710 as of 2026-11-09, down 11.7% from its all-time high of ₹3,069.85 but still trading above its 20/50/200-day moving averages (₹2,526.60 / ₹2,389.76 / ₹2,479.56). RSI at 60.9 signals neutral positioning — neither overbought nor oversold. The drawdown coincides with either broader market weakness or platform-specific concerns; the position above key averages suggests a held baseline of confidence. Ownership remains promoter-heavy: 65.57% promoter vs FII 0.05% and DII 0.63% as of FY-2026 Q4 (most recent filed). Latest QoQ saw FII tick up +0.05pp and DII +0.40pp while promoter trimmed 1.23pp — a mild rebalance but no institutional capitulation. No bulk/block deals flagged. The low FII/DII presence means institutional conviction is not driving the stock; upside will come from earnings delivery, not multiple re-rating.

It is a cycle of development till to approved. And you have to undergo certain trials as well as certain performances, which have to be proven.
29%, 30% margins sustainable. Revenues growing, economies of scale showing. Technologies in-house, cost will go down.
What to watch next — catalysts that resolve the debate
  • 1 · Kavach ISA certification milestone (Q3–Q4 FY27 or later)

    Trials ongoing; management evasive on approval timeline. ISA sign-off unlocks ₹100–120 Cr order book realization. If slips into FY28, the 40–50% CAGR thesis falters.

  • 2 · Fusion PCB utilization ramp (H2 FY27–FY28)

    Initial 30–40% PCBA capacity. Rate of ramp-up signals confidence in internal demand (locomotive subsystems) + external customers. Plateau or slow ramp = execution doubt.

  • 3 · Hydrogen propulsion system order execution (FY27–28)

    ₹3,100 HP locomotive delivery by next year. First hydrogen deployment after battery loco success. Delivery de-risks platform; delays flag supply chain or technical friction.

  • 4 · International partnerships revenue conversion (FY27–28 onwards)

    InnoTrans partnerships in motion. Management guided couple of million-dollar orders possible in current/next year. Track conversion pace to validate 1/4–1/2 global revenue by FY30 thesis.

Concord delivered a strong operational quarter — ₹159 Cr revenue (+95%), ₹846 Cr order book (4× annual), margin beat, and disciplined working capital. But the reported profit narrative (claiming 95% growth) doesn't square with the 80.2% actual: a sign that management is spinning the story, not just reporting it. The bull case is real, but execution-dependent: Kavach approval (₹100–120 Cr order), Fusion ramp (₹400 Cr target), hydrogen propulsion delivery (₹3,100 HP), and international partnerships (FY30 1/4–1/2 target) are all material and 12–24 months out.

The rating: Hold. The fundamentals are sound (order visibility, margin beat), but the platforms are early-stage, the regulatory approval is vague, and the customer concentration is high. A holder should stay the course on operational progress; a buyer should wait for one de-risking catalyst (Kavach approval or Fusion ramp-up confirmation) before averaging in.

The number to track: Order book execution rate (target ₹200–250 Cr annual run-rate) and EBITDA margin (watch for floor break below 28%).

Informational and educational content only. Not investment advice.